NEW YORK – Tempus said on Wednesday that it will collaborate with A2 Biotherapeutics to develop a companion diagnostic test for A2's loss of heterozygosity-targeted cell therapy platform, Tmod.
According to Tempus, the partnership could also expand in the future to include development of additional CDx tests for A2’s other clinical development programs.